drug_type
RELEVANT_DRUG
intervention_type
Biological (monoclonal antibody; immunotherapy)
drug_description
Subcutaneous anti-OX40 (TNFRSF4) IgG1 monoclonal antibody (AMG 451/KHK4083) that blocks OX40–OX40L costimulation and depletes OX40+ activated T cells via Fc-mediated cytotoxicity, reducing pathogenic Th2 responses in atopic dermatitis.
nci_thesaurus_concept_id
C184936
drug_mesh_term
Antibodies, Monoclonal
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Subcutaneous
drug_mechanism_of_action
Anti-OX40 (TNFRSF4) IgG1 monoclonal antibody that blocks OX40–OX40L costimulatory signaling and depletes OX40+ activated T cells via Fc-mediated cytotoxicity (e.g., ADCC), thereby reducing pathogenic Th2-driven inflammation in atopic dermatitis.
drug_name
Rocatinlimab
nct_id_drug_ref
NCT05724199